Elevated Serum Levels of CXC Chemokine Ligand-12 Are Associated with Unfavorable Functional Outcome and Mortality at 6-Month Follow-up in Chinese Patients with Acute Ischemic Stroke

详细信息    查看全文

• 作者：Xuan Cheng ; Ya-Jun Lian ; Yun-Qing Ma ; Nan-Chang Xie ; Chuan-Jie Wu
• 关键词：CXC chemokine ligand ; 12 ; Acute ischemic stroke ; Functional outcome ; Mortality ; Chinese
• 刊名：Molecular Neurobiology
• 出版年：2017
• 出版时间：March 2017
• 年：2017
• 卷：54
• 期：2
• 页码：895-903
• 全文大小：
• 刊物主题：Neurosciences; Neurobiology; Cell Biology; Neurology;
• 出版者：Springer US
• ISSN：1559-1182
• 卷排序：54

文摘

The aim of this study was to examine whether the circulating CXC chemokine ligand-12 (CXCL12) level can predict a 6-month outcome in Chinese patients with acute ischemic stroke (AIS). In a prospective study, CXCL12 levels were measured on admission in the serum of 304 consecutive patients with AIS. The prognostic value of CXCL12 to predict the functional outcome and mortality within 1 year was compared with the National Institutes of Health Stroke Scale score and with other known outcome predictors. A receiver operating characteristic (ROC) curve was used to evaluate the accuracy of serum CXCL12 in predicting functional outcome and mortality. Patients with an unfavorable outcome and non-survivors had significantly increased CXCL12 levels on admission (P < 0.0001 and P < 0.0001). Multivariate logistic regression analysis adjusted for common risk factors showed that CXCL12 (≥12.4 ng/mL; third quartile) was an independent predictor of functional outcome (odds ratio [OR] = 8.81; 95 % confidence interval [CI] 4.92–24.79) and mortality (OR = 10.15; 95 %CI 2.44–27.98). The area under the receiver operating characteristic curve of CXCL12 was 0.84 (95 % CI 0.76–0.92) for functional outcome and 0.87 (95 % CI 0.80–0.93) for mortality. Circulating CXCL12 serum levels at admission is a useful and complementary biomarker to predict functional outcome and mortality 6 months after acute ischemic stroke.